IMA 950

Drug Profile

IMA 950

Alternative Names: IMA950

Latest Information Update: 06 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator immatics biotechnologies GmbH
  • Developer Cancer Research UK; immatics biotechnologies GmbH; National Cancer Institute (USA); Oncovir; University Hospitals of Geneva
  • Class Cancer vaccines; Peptide vaccines; Peptides
  • Mechanism of Action T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Glioblastoma
  • Phase I Glioma

Most Recent Events

  • 06 Sep 2017 Immunogenecity and adverse events data from a phase I/II trial in Glioblastoma presented at the 3rd CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference (CRI-CIMT-EATI-AACR-2017)
  • 01 Jan 2017 Phase-I clinical trials in Glioma (Neoadjuvant therapy, Second-line therapy or greater, Combination therapy) in USA (SC) (NCT02924038)
  • 04 Oct 2016 University of California at San Francisco plans a pilot phase I trial for Glioma (Combination therapy, Second-line therapy or greater, Neoadjuvant therapy) in USA (SC) (NCT02924038)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top